Search

everythinglearnresearchcommunity

for

Search:↓

The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.

Follicum discovered that their drug FOL-005 increased hair count by 12 hairs per cm2 in patients with less than 255 hairs per cm2 and is planning a phase 2b trial. They are currently fundraising for the trial, and the drug may also be effective for women.

The user is considering stopping dutasteride and minoxidil due to side effects like low mood and depression after three weeks of use. They are concerned about hair shedding and are contemplating switching to just minoxidil to see if it helps without affecting mental health.

The conversation discusses using tretinoin as an additional treatment for hair loss alongside minoxidil, with plans to test its effectiveness by applying it to only one side of the scalp. The user intends to start this experiment after using minoxidil for a year.

The user is seeking advice on sourcing finasteride, dutasteride, and minoxidil, as their doctors are unwilling to prescribe both finasteride/dutasteride and minoxidil simultaneously. They are also looking for sources of GHK-Cu and RU58841 in the USA, with suggestions including using services like Hims, ro.co, and Musely.

Cutting sugar may not significantly impact hair loss, as DHT and androgen receptors are the main issues. Effective treatments include finasteride, dutasteride, RU58841, and minoxidil, often combined with microneedling.

The conversation is about when GT20029, a hair loss treatment, might be available on the grey market, with users discussing the challenges of compounding it and speculating it might be available after phase 2 results, similar to pyri. Specific treatments mentioned are pyri, RU58841, and GT20029.

Microneedling alone can stimulate hair growth and enhance the effectiveness of minoxidil. Combining microneedling with minoxidil is more effective than using minoxidil alone.

Veradermics' new hair loss treatment, VDPHL01, is likely a modified release oral minoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.

People are discussing their experiences with kx-826 (pyrilutamide) for hair loss, using concentrations of 0.5% and 0.9%. They are sharing personal results and progress with this treatment.